期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

西苯唑啉治疗肥厚型心肌病的研究进展 被引量：2

Research progress of cibenzoline in the therapy of hypertrophic cardiomyopathy
原文传递
导出
摘要 Ⅰa类抗心律失常药(西苯唑啉)被用于治疗室上性和室性心律失常。然而研究发现,苯唑啉还能显著降低肥厚型梗阻性心肌病梗阻部位的压差,提高肥厚心肌的舒张功能,改善患者的临床症状,长期使用安全、方便且效果稳定。本文总结临床上用其治疗各种类型肥厚型心肌病的实践经验,阐述西苯唑啉在心血管疾病方面的新应用,为肥厚型心肌病的患者提供新而有效的治疗方法,并探讨西苯唑啉治疗肥厚型心肌病的可能机制。 Class I antiarrhythmic drug cibenzoline once was used for su-praventricular or ventricular arrhythmias.However cibenzoline was found to decrease the pressure gradient significantly , at the same time improve the diastolic function and clinical symptoms of the obstructive hypertro-phic cardiomyopathy（HCM） safely, conveniently,stably in a long peri-od.This review was to investigate the mechanisms of treating HCM ,sum-marize the experience and explain the new application of cibenzoline.As a result , offering aneffective choice and reducing the adverse effect as well as promoting the quality of life of HCM patients.
作者 郭曦滢 樊朝美 李一石
机构地区 北京协和医学院 中国医学科学院 阜外心血管病医院 卫生部心血管药物临床研究重点实验室
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2014年第7期647-649,656,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家重大新药创制科技重大专项基金资助项目(2012ZX09303-008-001) 国家临床重点专科建设--《卫生部重点实验室项目》基金资助项目
关键词 西苯唑啉 梗阻 压差 肥厚型心肌病 心律失常 cibenzoline obstruction pressure gradient hypertrophic cardiomyopathy arrhythmias
分类号 R542.2 [医药卫生—心血管疾病]
  • 相关文献

参考文献22

  • 1HamadaM, Shigematsu Y, Ikeda S, et al. Class Ia antiarrhythmic drug cibenzoline : a new approach to the medical treatment of hyper- trophic obstructive cardiomyopathy [ J ]. Circulation, 1997,96 : 1520 - 1524.
  • 2Kajimoto K, lmai T, Minami Y, et al. Comparison of acute reduc- tion in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline[ J]. Am J Cardiol, 2010,106 : 1307 - 1312.
  • 3Hamada M, Aono J, Ikeda S, et al. Effect of intravenous adminis- tration of cibenzoline on left ventricular diastolic pressures in pa- tients with hypertrophic cardiomyopathy: its relationship to transmi- tral Doppler flow profiles [ J ]. Circ J, 2007,71 : 1540 - 1544.
  • 4Ozaki K, Sakuma I, Mitsuma K, et al. Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sigmoid - shaped septum [ J ]. Circ J, 2008,72:2087 - 2091.
  • 5KondoI, Mizushige K, Nozaki S, et al. Effect of cibenzoline on re- gional left ventricular function in hypertrophic obstructive cardiomy- opathy[ J]. Clin Cardiol, 2000,23:689 - 696.
  • 6Hamada M, Shigematsu Y, Hara Y, et al. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic func- tion in patients with hypertrophic cardiomyopathy [ J ]. Jpn Circ J, 2001,65:531 -538.
  • 7Sekine T, Daimon M, Hasegawa R, et al. Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstruc- tive cardiomyopathy[ J]. Heart Vessels, 2006,21:350 - 355.
  • 8Hamada M, Shigematsu Y, Inaba S, et al. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic ob- structive cardiomyopathy caused by midventrieular obstruction [ J ]. Circ J, 2005,69:940 -945.
  • 9Saito M, Okayama H, Yoshii T, et al. Myocardial fibrosis attenu- ates the effect of cibenzoline on left ventricular diastolic function in patients with hypertrophic cardiomyopathy [ J ]. J Cardiovasc Phar- macol, 2011,57:207 -212.
  • 10Hiasa G, Hamada M, Kodama K, et al. Apical hypertrophic car- diomyopathy associated with life - threatening paroxysmal atrial flatter with a slow ventricular response: a case report[ J]. Jpn. Circ J, 2000,64:225 - 228.

二级参考文献36

  • 1Marian A J, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol, 2001,33:655-770.
  • 2Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 2008,29:270-276.
  • 3Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol, 2011,57:2346-2355.
  • 4Fighali S , Krajcer Z, Edelman S, et al. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction. J Am Coil Cardiol, 1987,9 : 288 -294.
  • 5Poetter K, Jiang H, Hassanzadeh S,et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet, 1996,13:63-69.
  • 6Falicov RE, Resnekov L. Mid ventricular obstruction in hypertrophic obstructive cardiomyopathy. New diagnostic and therapeutic challenge. Br Heart J, 1977,39:701-705.
  • 7Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation, 1995,92 : 1680-1692.
  • 8Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation, 2008, 118 : 1541-1549.
  • 9Kawai M, Kihara Y, Hasegawa K, et al. Dilated phase of hypertrophic cardiomyopathy with mid-ventricular obstruction after 20-year follow-up. Jpn Circ J, 2000,64:6234526.
  • 10Seller C, Jenni R, Vassalli G, et al. Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy. Br Heart J, 1995,74:508-516.

共引文献4

同被引文献13

中国临床药理学杂志
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部